Regulatory Alerts

Keep up-to-date with key announcements and guidance from organisations including NICE, DHSC and MHRA.

Pralsetinib not recommended for RET fusion-positive advanced non-small-cell lung cancer

The clinical evidence for pralsetinib suggests it could be clinically effective, but its benefit is uncertain because it was not compared directly with any usual NHS treatments, says NICE. The treatment was rejected for both routine use and for use within the Cancer Drugs Fund.
Go to the profile of OnMedica
Aug 03, 2022